Russian regulator suspects cartel in domestic pharmaceutical market
The Russian Federal Anti-Monopoly Service (FAS) suspects R-Pharm, one of the country’s suppliers of drugs for state needs, is in illegal collusion with the country’s Ministry of Health, which may allow the company to receive large-scale contracts with the state, reports The Pharma Letter’s local correspondent.
According to the FAS, the Ministry of Health may be involved in the provision advantages to R-Pharm during state tenders for the purchase of drugs for state needs. Among these drugs are preparations against HIV, hepatitis B and C viruses, multidrug-resistant tuberculosis, and other antiviral and antibacterial drugs.
In addition, according to data from the FAS, R-Pharm violated contracts on the sum of 8 billion roubles (~$138 million), but was not disqualified from bidding.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze